1Monยท

$TMO (+0.81%) | Thermo Fisher Scientific Q3'24 Earnings Highlights:


๐Ÿ”น Adj EPS: $5.28 (Est. $5.25) ๐ŸŸข; DOWN -7.2% YoY

๐Ÿ”น Revenue: $10.60B (Est. $10.65B) ๐Ÿ”ด; UP +0.2% YoY


FY24 Guidance:

๐Ÿ”น Revenue: $42.48B-$43.38B (Est. $42.91B) ๐ŸŸก

๐Ÿ”น Adjusted EPS: $21.35-$22.07 (Est. $21.72) ๐ŸŸข


Q3 Segment Performance:

๐Ÿ”น Life Sciences Revenue: $2.39B (Est. $2.46B) ๐Ÿ”ด; DOWN -1.9% YoY


Operational Metrics (GAAP):

๐Ÿ”น EPS: $4.25 (Prev. $4.42 YoY)

๐Ÿ”น Operating Income: $1.84B (Prev. $1.86B YoY)

๐Ÿ”น Operating Margin: 17.3% (Prev. 17.6% YoY)

๐Ÿ”น Adj Operating Income: $2.36B

๐Ÿ”น Adj Operating Margin: 22.3% (Prev. 24.2% YoY)


New Product Launches:

๐Ÿ”ธ Thermo Scientific Iliad Microscope: Advances research in modern materials.

๐Ÿ”ธ Applied Biosystems MagMAX DNA/RNA Kit: Enhances genetic research in blood cancers.

๐Ÿ”ธ Vivofectamine Delivery Solutions: Enables nucleic acid delivery for new therapeutic applications.


Strategic Initiatives:

๐Ÿ”ธ Partnership with the National Cancer Institute for next-gen sequencing in precision medicine.

๐Ÿ”ธ Expansion of pharma services in Cincinnati, Ohio, and Bend, Oregon.

๐Ÿ”ธ New bioanalytical lab in Gothenburg, Sweden, to support biotech R&D.


CEO Marc N. Casper's Commentary:

๐Ÿ”ธ "We delivered strong financial results, reflecting sequential growth improvement. With our growth strategy and trusted partnerships, we are well-positioned to meet our 2024 objectives and build long-term value."

4
1 Comment

profile image
$TMO is the correct value
โ€ข
1
โ€ข
Join the conversation